Biotech Industry · global
Astellas secures licensing option for DAX-044, targeting the toxicity challenge of IL-12 cancer therapies
The collaboration, with a potential total value of approximately $1.34 billion, bets on a therapeutic design that concentrates immune stimulation in tumors. DAX-044 has not yet entered human trials, and Audax plans to begin a Phase 1 study in Australia in 2027.
Enabling the immune system to attack cancer cells more strongly may also come at a cost to the body. Concentrating immune stimulation in tumors while reducing systemic toxicity has long been a challenge for interleukin-12 (IL-12) cancer therapies. Astellas Pharma and Australia's Audax Biosciences announced a collaboration giving Astellas an exclusive global licensing option for the drug candidate DAX-044, establishing a development path for the therapy, which remains at the preclinical stage.
DAX-044 is an antibody-cytokine fusion protein that uses Audax's AVIKINE technology. According to the companies, it is designed to concentrate IL-12's immune-activating effects in the tumor microenvironment while limiting activity elsewhere in the body. The strategy aims to improve the balance between anticancer activity and toxicity; whether it can achieve this in humans remains subject to clinical validation.
The deal has a potential total value of approximately $1.34 billion, excluding royalties, but this is not a guaranteed payment amount. The upfront payment and a possible future option exercise payment total $285 million; the companies did not disclose the amounts separately. An additional amount of up to $1.05 billion is tied to development and commercial milestones. If the product receives marketing approval, Audax would also be eligible for tiered, double-digit percentage royalties on global net sales.
Audax continues to advance and fund development, including the work leading into Phase 1 trials. DAX-044 is undergoing preparatory development work needed to support an application or notification for human trials. In its own announcement, Audax also stated that it plans to begin a Phase 1 trial in Australia in 2027. This is a planned timeline and does not mean that the trial has been approved or has begun enrolling participants.
If Astellas exercises the option, it will assume responsibility for global development, manufacturing, and commercialization, while Audax retains the option to co-fund and co-promote the therapy in Australia and New Zealand. Exercising the option remains subject to relevant conditions, including applicable antitrust approvals. The agreement therefore gives Astellas the right to take over the program in the future, while completion of the full licensing arrangement remains conditional.
The companies' announcements stated that preclinical studies showed DAX-044 has the potential to improve the therapeutic index, meaning it could widen the margin between effective activity and toxicity. However, the announcements did not provide detailed data sufficient to independently assess this claim, and there are no human safety or efficacy results. It is therefore not yet possible to determine whether it can outperform other IL-12 therapy candidates.
The collaboration's next scientific test will come in human studies: whether the drug can trigger the intended tumor immune response at tolerable doses. For patients, the size of the deal signals resources for development; its actual therapeutic value must still be established progressively through subsequent trials.